Processing your request


please wait...

 | Investigations Dataset

Stanford Foreign Corrupt Practices Act Clearinghouse a Collaboration with Sullivan & Cromwell LLP

Investigations Dataset

 
Investigation into Pfizer's Activities in China · Pfizer Inc.

Information & Summary

Investigation into Pfizer's Activities in China

Related FCPA Matter:   Pfizer's Involvement in China Information

Information & Summary

Investigation Name:    Investigation into Pfizer's Activities in China

Trend:    None

Type of investigation:    SEC, DOJ

Agencies Investigating/Assisting with SEC/DOJ Investigation:   

Whistleblower:    Unknown

Summary

Pfizer Inc. is a global pharmaceutical company that discovers, develops, manufactures and markets prescription medicines for humans and animals. Pfizer is incorporated in the State of Delaware and is headquartered in New York, New York. Its securities are registered with the Commission under Section 12(b) of the Exchange Act, and its common stock trades on the New York Stock Exchange under the symbol “PFE.”

In its 10-Q filed on November 5, 2020, Pfizer disclosed that it had received an informal request from the DOJ's FCPA Unit seeking documents relating to the company's operations in China. The SEC's FCPA Unit made a similar request in August 2020. Pfizer said it was producing records pursuant to those requests.

This investigation is ongoing.

Protected Content


Please Log In or Sign Up for a free account to access restricted features of the Clearinghouse website, including the Advanced Search form and the full case pages.

When you sign up, you will have the option to save your search queries performed on the Advanced Search form.